Physician profile
Muhammad A Arida
NPI 1053528554
$10,057.28
in general payments reported to CMS, 2019-2025
42 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,842 · 2020: $418 · 2021: $1,067 · 2022: $1,314 · 2023: $1,631 · 2024: $2,673 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385 · Travel and Lodging: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,384.86 |
| Travel and Lodging | $1,031.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,142.93 | 2021-2025 | Symplicity G3, Onyx Frontier, Reveal Linq |
| Amgen INC. | $1,039.64 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $838.44 | 2019-2025 | |
| Abiomed | $752.41 | 2019-2025 | Impella |
| Shockwave Medical, INC | $632.33 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Abbott Laboratories | $607.92 | 2021-2025 | Pressurewire, Optis, Dragonfly Opstar |
| Janssen Pharmaceuticals, INC | $501.40 | 2019-2024 | Xarelto |
| Pfizer INC. | $339.60 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $326.40 | 2019-2025 | Lifevest |
| Penumbra, INC. | $300.47 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $231.15 | 2019-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $226.13 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.84 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $195.90 | 2019-2022 | |
| Heartflow, INC. | $172.43 | 2019-2024 | Ffrct |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $137.74 | 2019-2022 | |
| Esperion Therapeutics, INC. | $132.78 | 2021-2025 | Nexletol |
| Terumo Medical Corporation | $122.64 | 2020-2023 | Glidewire, Heartrail, Metacross Otw |
| Chiesi USA, INC. | $118.19 | 2020-2025 | Kengreal |
| Regeneron Healthcare Solutions, INC. | $110.96 | 2019 | |
| Amarin Pharma, INC. | $108.99 | 2019-2022 | |
| Teleflex LLC | $105.53 | 2025 | Twin-Pass, Turnpike |
| Cvrx, INC. | $104.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $98.38 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $85.56 | 2021-2024 | Verquvo, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $55.78 | 2022-2023 | |
| Lundbeck LLC | $51.41 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $41.51 | 2019 | |
| Gilead Sciences, INC. | $36.28 | 2019 | |
| Flowphysix INC | $33.61 | 2025 | Flowrunner |
| Boston Scientific Corporation | $31.34 | 2020-2025 | Avvigo Guidance System |
| Novo Nordisk INC | $30.66 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Cardiovascular Systems INC. | $27.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.69 | 2019 | |
| Scpharmaceuticals INC. | $21.11 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $16.78 | 2023 | Inpefa |
| Lantheus Medical Imaging, INC. | $15.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.84 | 2019 | |
| Ge Healthcare | $13.37 | 2020 | |
| Medtronic Vascular, INC. | $13.34 | 2019 | |
| Altathera Pharmaceuticals LLC | $1.39 | 2025 | Sotalol Hydrochloride |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Arida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.